---
title: Optimal-medical-therapy-stable ischemic heart disease
---

- from: [[stable ischemic heart disease]] 󰒖

# Optimal-medical-therapy-stable ischemic heart disease

- ASA 75–162 mg/d;
  - can substitute clopi if ASA-intolerant.
  - ~12 mos after PCI,
  - clopi monoRx ↓ risk of ischemic and bleeding events by ~30% c/w ASA monoRx (Lancet 2021;397:2487).
- βB for 3 years post-MI or if ↓ EF;
  - can consider in all Pts w/ SIHD
- ACEI (or ARB if intolerant of ACEI) if
  - HTN,
  - DM,
  - CKD,
  - ↓ EF (Lancet 2006;368:581)
- Dual antiplatelet therapy (ASA + P2Y12 inhibitor):
  - ↓ CV events by ~10% in Pts with known IHD w/o MI but w/ DM,
  - but ↑ bleeding (THEMIS, NEJM 2019; 381:1309)
- Rivaroxaban 2.5 mg bid + ASA 100 mg/d:
  - 24% ↓ CV events and 18% ↓ death vs. ASA alone,
  - but ↑ major bleeding in stable ASCVD (COMPASS, NEJM 2017;377:1319)
- Colchicine (0.5 mg/d)
  - ↓ CV events by 31%,
  - but ? ↑ non-CV death (NEJM 2020;383:1838)
- Medical therapies for symptomatic relief (Circ 2014;130:1749)
  - Beta-blockers 1st-line therapy; CCB (except short-acting dihydropyridines)
  - Long-acting nitrates
  - Ranolazine (↓ late inward Na+ current to ↓ myocardial demand): 2nd-line anti-anginal
